Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.65+0.03 (+0.22%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
Trevi Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Trevi Therapeutics's enterprise value was $1.79B on Nov 11, 2026, against $1.50B a year earlier. Over the last 5 years it ranged from -$18.59M to $2.22B, with a median of $144.29M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.79B | +27.0% |
| 2025 | Dec 31, 2025 | $1.41B | +474.8% |
| 2024 | Dec 31, 2024 | $245.38M | – |
| 2023 | Dec 29, 2023 | -$3.30M | – |
| 2022 | Dec 30, 2022 | -$13.04M | – |
| 2021 | Dec 31, 2021 | -$14.81M | – |
| 2020 | Dec 31, 2020 | -$8.96M | -366.2% |
| 2019 | Dec 31, 2019 | $3.36M | – |
See a number that looks wrong?